Posts

Sidewinder Therapeutics Announces $137 Million Series B Financing for Bispecific ADC Development

on

Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Scientific Advisory Board

on

Rakovina Therapeutics Q3 2025 Financial Results and Corporate Update

on

Novartis Announces Fourth US Radioligand Therapy Facility in Winter Park, Florida

on

Novartis Announces Fourth US Radioligand Therapy Facility in Winter Park, Florida

on

Novartis Announces Fourth US Radioligand Therapy Facility in Winter Park, Florida

on

Rakuten Medical Raises $100 Million in Oversubscribed Series F for Photoimmunotherapy Platform

on

NiKang Therapeutics Presents NKT5097: First-in-Class CDK2/4 Dual Degrader at SABCS 2025

on

Ratio Therapeutics Appoints Marcel Reichen as Chief Strategy Officer

on

Takeda and Innovent Forge $1.2B Upfront Oncology Pact for Bispecific and ADC Therapies, Total Deal Valued Up to $11.4B

on

Boehringer Ingelheim Strikes Nearly $1B ADC Deal with AimedBio; EyePoint Pharmaceuticals Announces $150M Stock Sale

on

Glenmark Pharma Signs $1.1 Billion Deal with Hengrui for HER2-Targeted Antibody-Drug Conjugate

on

Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO

on

Bayer Expands Oncology Pipeline with $1.3B Kumquat Deal

on

Replimune Awaits FDA Direction After Complete Response Letter for Advanced Melanoma Therapy

on

ARTBIO Raises $132M Series B to Advance Alpha Radiotherapy Pipeline and Manufacturing with Pb212

on

Dispatch Bio Launches with $216M and CAR-T Pioneer Carl June to Advance Universal Solid Tumor Immunotherapy

on

Sino Biopharm Acquires Merck's PD-1xVEGF Bispecific Partner LaNova for up to $951M

on

BioNTech Halts Cell Therapy Manufacturing at Maryland Site, Lays Off Dozens

on

BioNTech to Acquire CureVac in $1.25B All-Stock mRNA Deal

on